05:18 PM EST, 02/03/2025 (MT Newswires) -- Revive Therapeutics ( RVVTF ) after trade Monday provided an update on its work with Bucillamine, an oral drug with anti-inflammatory and antiviral effects that has been safely used to treat rheumatoid arthritis in Japan and South Korea.

The company said it is focusing on two key areas for its research and development: medical countermeasures and infectious diseases.

For medical countermeasures, Revive is evaluating Bucillamine as a potential treatment for nerve agent exposure, working with Defence R&D Canada. The research is expected to finish by February. In the infectious diseases area, the company is targeting long COVID, which affects millions of people. It plans to submit a phase 2 clinical study protocol to the Food and Drug Administration by the end of first quarter, aiming for approval by the second quarter.

The company also said it has agreed to a consent judgment regarding an arbitration award involving a service provider. The company plans to settle the award by May.